Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers compared outcomes between babies born to HIV-positive mothers exposed to antiretrovirals and those who were not.
Researchers examined outcomes among a group of people in middle- and low-income nations who switched to the integrase inhibitor.
Among those taking Epivir, taking two antiretrovirals instead of three was tied to fewer people stopping because of side effects.
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
A South African study found that this cost-savings measure did not change the likelihood of viral suppression after 48 weeks.
Janssen’s single-tablet antiretroviral regimen was approved on July 17.
A recent study compared birth outcomes among HIV-positive women exposed to various antiretroviral regimens.
Researchers identified treatment with Kaletra (lopinavir/ritonavir) as a risk factor.
A recent analysis of Europeans taking boosted protease inhibitors for HIV treatment found this pair prompted the best long-term response.
Neither age nor body weight were significantly associated with type 2 diabetes among older people with HIV in a recent study.
In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.
Results from a Phase III trial showed Symtuza worked as well as a boosted protease inhibitor–based antiretroviral regimen.
Having taken Kaletra also raised the risk of erectile dysfunction in a recent study of this group.
Sustiva (efavirenz), which is included in Atripla, is associated with central nervous system side effects and sleep disturbances.
An unacceptably high rate of mother-to-child transmission of HIV still occurs in many African nations, often through breast feeding.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.